Biosimilars Market Growth Accelerated by Increasing Demand for Cost-Effective Drugs

 

Biosimilar Market

Biosimilars are biologic medications designed to be similar to an existing FDA approved reference biologic product. Biosimilars are meant to provide affordable alternatives to expensive biologic therapies after biological patents expire. Biosimilars improve patient access to lifesaving therapies in areas such as oncology, immunology and hematology. The global biosimilars market is estimated to be valued at US$ 29.4 Bn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

 

Market Dynamics:

One of the major driver fueling the growth of the biosimilars market is the increasing patent expiry of blockbuster biologics. Between 2018 to 2024, biologics such as AbbVie's Humira, Pfizer's Neupogen, Genentech's Rituxan, and Johnson & Johnson's Remicade with a combined sales value of over $35 billion will go off-patent, opening the gateway for biosimilars entry. The emergence of biosimilars also represents considerable cost savings compared to reference biologics which are highly priced. According to the European Commission, biosimilars have the potential to save European healthcare systems nearly €100 billion in 2014-2020 as a result of lower average medicine prices. This cost saving along with improved access to treatment are expected to drive the future adoption of biosimilars over the forecast period.

 

SWOT Analysis

Strength: Biosimilars are nearly identical copies of original biologic drugs and provide more treatment options at lower costs compared to reference biologics. Biosimilars can treat various chronic diseases by mimicking the pharmacological effects of original biologics. With established manufacturing processes, biosimilars can gain quick regulatory approvals.

 

Weakness: Developing biosimilars require huge capital investments and specialized research expertise due to complexity in replicating biologic molecules. Biosimilars may face patent litigations from reference drug companies which can delay market entry. Limited substitutability and interchangeability provisions restrict automatic substitution of biosimilars for prescribed reference biologics in some regions.

 

Opportunity: Patent expiry of major biologic drugs provide opportunities to introduce affordable biosimilar versions, increasing patient access to treatments. Growing prevalence of chronic diseases worldwide will augment the demand for cost-effective biologics and biosimilars. Favorable regulatory guidelines and incentive programs in several countries promote biosimilars usage.

 

Threats: Unfavorable pricing policies and limited reimbursement coverage pose challenges in biosimilars commercialization. Heightened competition from emerging biosimilars players may erode brands and compress margins. Adverse drug reactions and immunogenicity issues attributed to biosimilars can harm market reputation and future sales. Stringent pharmacovigilance requirements increase regulatory compliances cost burden.

 

Key Takeaways

The Global Biosimilars Market Share is expected to witness high growth over the forecast period of 2023-2030. The market size is estimated to reach US$ 29.4 Bn by 2024, expanding at a CAGR of 5.9% through 2030.

 

Regional analysis - Europe dominates currently due to an established regulatory framework and incentive programs supporting biosimilar approvals and usage. However, the Asia Pacific region is expected to offer lucrative opportunities with emerging biosimilars industries in China, India and South Korea. Favorable regulatory guidelines and rising healthcare spending will accelerate biosimilars market growth in Asia Pacific region during the forecast period.

 

Key players - Key players operating in the biosimilars market include U.S. Environmental Protection Agency (EPA), European Chemicals Agency (ECHA), Food and Drug Administration (FDA), and Ministry of Health, Labour and Welfare (MHLW). These regulatory agencies play a critical role in establishing guidelines and approving biosimilars.


Get More Insights Here

 

https://techaxen.com/rise-of-surgical-robots-in-healthcare-industry/

https://www.newswirestats.com/biosimilars-market-size-share-growth-outlook-2023/

 

Comments

Post a Comment

Popular posts from this blog

"Global Heparin Market: Current Trends and Future Prospects"

Image
  Heparin, a crucial anticoagulant, has been a mainstay in the pharmaceutical industry for many years. It plays a pivotal role in preventing and treating conditions such as deep vein thrombosis, pulmonary embolism, and various cardiovascular diseases. As we delve into the current state of the heparin market, we will explore the trends, challenges, and opportunities that shape this vital segment of the pharmaceutical industry. Market Overview: The global heparin market has experienced steady growth over the years, driven by an aging population, increasing cases of cardiovascular diseases, and a rising awareness of the importance of anticoagulants in healthcare. Heparin is available in various forms, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH), each with its own set of applications and market dynamics. Trends: 1.      Rising Demand for LMWH : Low molecular weight heparin is gaining popularity due to its ease of administr...
Read more

"Advancements in Cystic Fibrosis Treatment: A Comprehensive Market Analysis"

Image
  The cystic fibrosis market has seen significant advancements and changes in recent years. Cystic fibrosis is a genetic disorder that affects the lungs and digestive system, leading to thick and sticky mucus production that can cause serious respiratory and digestive complications. The introduction of new therapies and treatments, such as CFTR modulators, has revolutionized the management of cystic fibrosis, offering hope and improved quality of life for patients. These drugs target the underlying genetic mutations responsible for the condition, helping to alleviate symptoms and slow disease progression. However, challenges remain in the cystic fibrosis market . Access to these ground-breaking therapies can be limited due to high costs, and ongoing research is needed to develop treatments for all genetic mutations associated with the disease. Additionally, the market continues to evolve as new therapies and innovations emerge. Collaborative efforts between pharmaceutical compani...
Read more

Botanical Packaging is Estimated to Witness High Growth Owing to Growing Environmental Concerns

Image
  Botanical Packaging Market Botanical packaging involves using various plant-based materials like corn starch, wheat starch, soy protein, bamboo, bagasse as raw materials for manufacturing boxes, cartons, bags and wrapping films for packaging applications. These biodegradable materials offer attractive sustainability advantages over traditional petroleum-based plastics. Botanical packaging finds widespread application in food, beverage, pharmaceutical, personal care and homecare industries for primary, secondary and tertiary packaging needs. The global botanical packaging Market is estimated to be valued at US$ 138.24 Bn in 2023 and is expected to exhibit a CAGR of 34% over the forecast period 2024 to 2031.   Market Dynamics: Growing environmental concerns about the menace of plastic pollution have been fuelling adoption of sustainable packaging alternatives globally. One of the key drivers for botanical packaging market is the stringent government policies and regulati...
Read more